Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating restated by equities researchers at Credit Suisse Group in a research report issued on Tuesday. They currently have a $201.00 price target on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective indicates a potential upside of 228.27% from the company’s previous close.

Several other equities analysts have also weighed in on the stock. Cowen and Company restated an “outperform” rating and issued a $232.00 price objective on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. Wells Fargo & Company reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Jefferies Group LLC initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, July 10th. They issued a “buy” rating and a $275.00 target price for the company. Cantor Fitzgerald reaffirmed an “underweight” rating and issued a $69.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Intercept Pharmaceuticals currently has an average rating of “Hold” and an average target price of $164.15.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The business had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. During the same period in the prior year, the business posted ($3.14) earnings per share. Intercept Pharmaceuticals’s revenue was up 459.6% compared to the same quarter last year.

TRADEMARK VIOLATION WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/26/intercept-pharmaceuticals-inc-icpt-rating-reiterated-by-credit-suisse-group.html.

In related news, Director Daniel G. Welch sold 602 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $123.93, for a total value of $74,605.86. Following the completion of the transaction, the director now owns 3,108 shares of the company’s stock, valued at $385,174.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel G. Welch sold 217 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total transaction of $27,506.92. Following the completion of the transaction, the director now directly owns 3,710 shares of the company’s stock, valued at approximately $470,279.60. The disclosure for this sale can be found here. Insiders have sold 8,013 shares of company stock valued at $966,747 in the last three months. 4.50% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in ICPT. MARSHALL WACE ASIA Ltd bought a new position in Intercept Pharmaceuticals in the first quarter valued at $13,012,000. Marshall Wace North America L.P. bought a new position in Intercept Pharmaceuticals in the first quarter valued at $13,012,000. Balyasny Asset Management LLC bought a new position in Intercept Pharmaceuticals in the second quarter valued at $13,766,000. Macquarie Group Ltd. grew its position in Intercept Pharmaceuticals by 54.2% in the first quarter. Macquarie Group Ltd. now owns 241,565 shares of the biopharmaceutical company’s stock valued at $27,321,000 after purchasing an additional 84,954 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Intercept Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after purchasing an additional 57,149 shares in the last quarter. 82.19% of the stock is owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.